Clinical trials: Glucose Tolerance
Continuous Glucose Monitoring, Oral Glucose Tolerance
Non-Nutritive Sweetener Consumption and Glucose Homeostasis in Older Adults With Prediabetes
Animal and observational research in humans suggest that specific types of non-nutritive sweeteners (NNS) may impair glycemic control.
- Conditions
- Continuous Glucose Monitoring, Oral Glucose Tolerance, Insulin Sensitivity, Inflammatory Markers
- Trial name
- NCT05337098
- Testing
- Non-Nutritive Sweetener Intake and impact on glucose homeostasis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Polytechnic Institute and State University
PreDiabetes, Hyperglycemia
Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs
The purpose of this research study is to compare the effectiveness of a fully automated digital diabetes prevention program to standard of care human coach-based diabetes prevention programs for promoting clinically meaningful…
- Conditions
- PreDiabetes, Hyperglycemia, Glucose, High Blood, Overweight
- Trial name
- NCT05056376
- Testing
- Digital Diabetes Prevention Program (dDPP), Human Coach-based Diabetes Prevention Program (hDPP)
- Where
- 2 sites in United States
- Volunteers
- 368 people
- Sponsor
- Johns Hopkins University
Abnormal Glucose Tolerance, Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM.
- Trial name
- NCT01773707
- Testing
- CTLA4-Ig (Abatacept)
- Where
- 17 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Impaired Glucose Tolerance
Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance
Resveratrol is a substance found in many plants, including grapes and red wine, which is widely used as a nutritional supplement.
- Trial name
- RSV (NCT01375959)
- Testing
- resveratrol
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Albert Einstein College of Medicine
PreDiabetes, Impaired Fasting Glucose (IFG)
Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.
This study evaluates the effect of different doses of metformin on the function of endothelium in people with pre-diabetes. One group of the patients will receive metformin in dose: 1500 mg, the second one will receive 3000…
- Conditions
- PreDiabetes, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT)
- Trial name
- NCT03398356
- Testing
- Metformin
- Where
- Poland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Impaired Glucose Tolerance
Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance
Purpose of the study: to assess the efficacy of Subetta in the treatment of impaired glucose tolerance to assess the safety of Subetta in the treatment of impaired glucose tolerance.
- Trial name
- NCT03725033
- Testing
- Subetta
- Where
- 44 sites in Russia
- Volunteers
- 538 people
- Sponsor
- Materia Medica Holding
Impaired Glucose Tolerance
Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Prediabetes (PD) was defined as an state in which glucose levels are above normal but not enough to meet criteria for the diagnosis of type 2 diabetes (T2D).
- Trial name
- NCT02708966
- Testing
- Gymnema Sylvestre
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Prediabetes, Impaired Fasting Glucose
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Prediabetes is a term that refers to alterations in glucose homeostasis, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, involving a higher risk of progression type 2 diabetes mellitus (T2DM).
- Conditions
- Prediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
- Trial name
- NCT02700334
- Testing
- Dapagliflozin
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Impaired Glucose Tolerance, Oxidative Stress
Effect of Dietary Glycemic Index on Beta-cell Function
The study will determine if increasing the highs and lows of blood glucose levels (glycemic variability) impairs insulin secretion in people with impaired glucose tolerance and/or impaired fasting glucose who are at risk for…
- Conditions
- Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
- Trial name
- GIdiet (NCT01386645)
- Testing
- low glycemic index (LGI) diet, high glycemic index diet plus N-acetylcysteine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Impaired Glucose Tolerance
Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation
The purpose of the study is to examine the effect of saxagliptin, an anti-diabetes medication, on hepatic and myocardial fat content and monocyte inflammation in patients with Impaired Glucose Tolerance (IGT).
- Trial name
- NCT01548651
- Testing
- Saxagliptin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Baylor College of Medicine
Impaired Glucose Tolerance
Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others.
- Trial name
- NCT02621060
- Testing
- Chlorogenic acid
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and…
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT01234649
- Testing
- Metformin XR plus liraglutide
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Woman's
Impaired Glucose Tolerance
Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
The purpose of this study is to determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in participants with impaired glucose tolerance in the routine clinical…
- Trial name
- NCT01993927
- Testing
- Voglibose
- Where
- Japan
- Volunteers
- 742 people
- Sponsor
- Takeda
Pre-diabetes, Impaired Fasting Glucose
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
- Conditions
- Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
- Trial name
- NCT01488279
- Testing
- Dexamethasone 2.5 mg and Sitagliptin 100 mg
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Type 2 Diabetes, Healthy
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin sensitivity in skeletal muscle, liver, and fat cells.
- Conditions
- Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
- Trial name
- PIO-EX (NCT00845182)
- Testing
- Pioglitazone, Exenatide, Pioglitazone and Exenatide
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Impaired Glucose Tolerance (IGT), Diabetes
Acute Effect of Exenatide on Brain Glucose Metabolism
This research study will examine brain glucose metabolism after an overnight fast to determine the effect of exenatide on brain glucose metabolism and lipid metabolism.
- Trial name
- NCT01588418
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Obesity, Impaired Glucose Tolerance
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes.
- Trial name
- NCT00456885
- Testing
- exenatide
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Impaired Glucose Tolerance
Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis
The purpose of this study is to determine the effect of chronic PDE5 inhibitor therapy on glucose metabolism in persons with prediabetes.
- Trial name
- NCT01409993
- Testing
- Sildenafil, Hyperglycemic clamp, Euglycemic clamp
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Vanderbilt University
Impaired Glucose Tolerance, Type 2 Diabetes
Actos Now for Prevention of Diabetes (ACT NOW)
The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus
- Trial name
- NCT00220961
- Testing
- Pioglitazone
- Where
- 8 sites in United States
- Volunteers
- 602 people
- Sponsor
- The University of Texas Health Science Center at San Antonio